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The immune system has been implicated in a myriad of 
different contexts, such as cancer, neurological 
disorders and aging. Tissue homeostasis is maintained 
through multiple regulatory mechanisms, among which 
the immune system. Deregulation of immune responses 
can in turn lead to tissue pathology and disease. Thus, 
understanding the mechanisms that regulate immune 
responses has been a focus of different fields within the 
scientific community. In recent years, an intriguing 
metabolite has been explored for its broad immuno-
modulatory properties, itaconate.  
Itaconate has long been manufactured from the fungi 
Aspergillus species and used as a multi-functional 
industrial biomaterial. However, the last years have 
uncovered novel facets of itaconate in mammalian 
systems. Activated immune cells, chiefly of the myeloid 
lineage, have an increased expression of the immune-
responsive gene 1 (IRG1) mitochondrial enzyme, which 
catalyses the decarboxylation of the Krebs cycle inter-
mediate cis-aconitate to itaconate. On one hand, 
itaconate has direct antibacterial properties, since it can 
inhibit bacterial growth in glucose-poor conditions. 
Notably, some bacteria can degrade itaconate to 
pyruvate and acetyl-CoA and thus survive in the 
eukaryotic host. These detoxifying pathways could also 
confer advantage against itaconate-producing fungi. On 
the other hand, in inflammatory conditions, the rising 
levels of itaconate have an extremely relevant role in 
keeping in check the inflammatory response. Lipo-
polysaccharides and type I interferons induce increased 
IRG1 expression and the production of the latter is 
limited by itaconate, indicating a regulatory negative 
feedback loop [1]. 
The molecular mechanisms under control by itaconate 
vary, but the net function is considered to be anti-
inflammatory. Itaconate acts as a competitive succinate 
dehydrogenase (SDH) inhibitor, impairing the electron 
transport chain (ETC) with a concomitant succinate 
accumulation [2]. SDH is both an enzyme of the Krebs 
cycle, oxidizing succinate to fumarate, and the 
component of complex II of the ETC, feeding electrons 
derived from succinate oxidation to the ubiquinone 
pool. Itaconate has also been shown to inhibit fructose-
6-phosphate 2-kinase and thereby possibly blocks the 
increased glycolysis of pro-inflammatory macrophages. 
Itaconate reacts with thiols, forming adducts with gluta- 
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thione, the major cellular antioxidant, and producing 
higher levels of reactive oxygen species (ROS) [3]. The 
antioxidant Nrf2 pathway is then activated in the 
presence of itaconate, possibly indirectly due to the 
increased ROS production, but also due to direct 
alkylation of cysteine residues of the Nrf2 inhibitor 
Keap1 [1]. Ultimately, there is enhanced expression of 
antioxidant and a decreased expression of pro-inflam-
matory genes, due to the induction of Nrf2 and the 
transcription factor ATF3 [3], respectively. Interes-
tingly, it has been suggested that itaconate increases the 
level of MHC class I in macrophages. However, its 
influence on antigen presentation remains to be ex-
plored. In addition, itaconate could conceptually 
regulate gene expression through epigenetic alterations. 
It sequesters glutathione, thereby possibly influencing 
histone glutathionylation and the levels of the methy-
lation substrate s-adenosyl methionine (SAM). 
Moreover, an intermediate of itaconate catabolism has 
been negatively implicated in vitamin B12 metabolism 
[4]. The reduced levels of B12 affects methionine and 
folate cycles, relevant for not only glutathione synthesis 
and redox homeostasis but also for SAM levels and 
histone and DNA methylation.  
The immunosuppressive effects of itaconate have been 
explored in various disease models, such as cardiac 
ischemia reperfusion injury, psoriasis, cancer and infec-
tion. In in vivo mouse models, intravenous 
administration of itaconate reduces myocardial infarct 
size [2], while the induction of psoriasis with itaconate 
treatment prevented the typical scaling and edema of the 
skin [3]. In a peritoneal tumor mouse model, high 
itaconate levels in tumor associated macrophages pro-
mote tumor progression. Itaconate plays important roles 
during infection, decreasing tissue injury in a 
Mycobacterium tuberculosis infection mouse model [5] 
and increasing macrophage bactericidal activity in a 
zebrafish model. Interestingly, itaconate altered 
neuronal metabolism to suppress viral replication in a 
mouse model of Zika virus infection [6], indicating that 
the modulatory effects of itaconate are not curtailed to 
cells of the myeloid lineage.  
Itaconate could also be a possible modulator of 
maladaptive immune programs. In sepsis, the exa-
cerbated inflammatory response to infection is counter-
acted by the induction of tolerance, which can lead to 
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immune paralysis and an increased susceptibility to 
secondary infections. Monocyte immune tolerance is 
promoted by itaconate, which decreases the production 
of pro-inflammatory mediators. Heme oxygenase 1, a 
cytoprotective enzyme that limits inflammation, is 
expressed during tolerance and has also been shown to 
regulate IRG1 expression. In contrast, the immune 
system can be hyperactivated. Particularly, the innate 
immune system can be primed to exhibit an increased 
responsiveness upon a second non-related insult, 
mirroring an immunologic memory which was coined 
trained immunity [7]. One stimulus that can exert 
trained immunity in monocytes is the C. albicans cell 
wall component β-glucan. It has been recently described 
by our group that β-glucan-induced training can prevent 
endotoxin tolerance [8]. Exposure to β-glucan inhibits 
the increased IRG1 expression and thus preserves a 
functional SDH pathway and the integrity of the Krebs 
cycle. Interestingly, exposure to itaconate can also 
inhibit the induction of β-glucan trained immunity. In 
this model, itaconate is also considered to have anti-
inflammatory effects, regulating tolerance positively 
while decreasing trained immunity.  
In conclusion, itaconate metabolism could be both a 
possible therapeutic target and a tool in inflammatory 
and autoimmune diseases with altered immune 
responses. Further exploration of the molecular, meta-
bolic and epigenetic changes induced by itaconate in 
different cell types and disease models will be of great 
importance, in order to better establish the potential of 
the modulation of this promising metabolite and open 
new therapeutic avenues.  
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